Vicor Technologies, Inc. Reports Expanded Sales Force Driving Revenue Growth

BOCA RATON, FL--(Marketwire - February 08, 2011) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company’s continually expanding nationwide network of independent sales representatives is driving sales of its PD2i Analyzer™ and revenue growth. Vicor Technologies (http://www.vicortech.com) is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

Revenues from sales of Vicor’s PD2i Analyzer™ during January 2011 were $77,000 as compared with total revenues of $69,000 for the fourth quarter of 2010 and $190,000 for all of 2010. According to Christopher Vissman, who joined Vicor as National Sales Manager in mid September 2010, the Company now has 34 independent sales representatives targeting physicians specializing in endocrinology, internal medicine, cardiology, and family medicine in 16 states across the United States: AZ, CA, CO, FL GA, MA, MD, MO, MS, NC, NJ, NV, NY, OH, SC, TN, and TX.

“The trend indicated by January sales is very exciting. Within the first month of 2011, Vicor realized revenues in excess of revenues realized during the entire fourth quarter of 2010 and reached 40% of revenues for all of 2010. As we continue to add new sales representatives, we anticipate we will continue to reap revenues from increased unit sales and tests. The response from physicians -- whether in family or internal medicine, endocrinology or cardiology -- has been very positive, and extremely gratifying,” stated Mr. Fater.

The Vicor sales force is composed of independent representatives who have worked with companies such as St. Jude Medical, Medtronic, Biotronik, Sorin Group, GE Healthcare, Hill-Rom, Stryker, CardioDynamics, Polymedco, Becton, Dickinson and Company, Intelli-Heart, eCardio, and CarboMedics.

“With backgrounds like theirs, we’re confident that our sales force is well-established among the physicians we’re targeting and will continue to have a significant impact on our revenue growth going forward, especially as we continue to aggressively add independent representatives supplemented by our own direct regional sales managers,” Mr. Fater concluded.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials, risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions, such as St. Jude Medical, Medtronic, Biotronik, Sorin Group, GE Healthcare, Hill-Rom, Stryker, CardioDynamics, Polymedco, Becton, Dickinson and Company, Intelli-Heart, eCardio, and CarboMedics, in this media release does not constitute endorsement by these institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ, including but not limited to: the ability of our sales force to continue to generate revenue growth; our ability to hire additional independent sales representatives who contribute to revenue growth; our ability to successfully complete the normal range study for PD2i® values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA™(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People’s Republic of China; our ability to develop additional applications for the PD2i® algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 11-07

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: biotechnology medical devices cardiac death diabetes autonomic neuropathy trauma diagnostics